MedicalDevice Licensing.com
Innovaro Pharmalicensing
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Innovaro Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Pay-per-Click New!
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Innovaro Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd
Innovaro Corporation
Out-licensing

Predictive Test for Age-Related Macular Degeneration in Asymptomatic Individuals

National Institutes of Health (NIH)
A rapid, accurate and affordable genetic screen, utilizing DNA microarray technology on a single chip

Full description

Predictive Test for Age-Related Macular Degeneration in Asymptomatic Individuals

 

 

Description of Technology: 

Age-related macular degeneration (ARMD) is the leading cause of severe, irreversible vision loss for those over the age of fifty in the United States and in other developed countries.  Thirteen million Americans over the age of forty have ARMD.  ARMD is caused by the deterioration of the central area of the retina, or macula, resulting in a loss of central vision.  This disease is believed to be a multigenic disorder, and is triggered by environmental factors such as smoking, age or diet in genetically susceptible individuals.

 

The present invention describes a highly predictive genetic test for universal practical clinical use to identify individuals at increased risk for ARMD.  It comprises a rapid, accurate and affordable genetic screen, utilizing DNA microarray technology on a single chip.  Sixteen genes are screened for 90 mutations/polymorphisms associated with ARMD, with a high predictive power (up to 92.7%) to identify asymptomatic carriers at risk.  Accurate prediction of genetic susceptibility to this disorder will allow interventions to protect at-risk individuals.

 

Applications: 

  • Method to diagnose ARMD
  • Diagnostic kit to identify asymptomatic individuals at risk for ARMD
  • Method to identify genetic factors in an affected individual, aiding in the development of a tailored therapeutic plan
  • Provide genetic epidemiologic data to elucidate the role of genetic factors in the progression of the disease

 

Advantage: 

Easy, rapid high-throughput method to diagnose ARMD

 

Development Status: 

This technology requires analytic validation before commercialization.

 

Patent information

  • U.S. Patent Application No. 12/089,694 filed 09 Apr 2008 (HHS Reference No. E-023-2006/0-US-07)
  • Australian Patent Application No. 2006311966 filed 02 Nov 2006 (HHS Reference No. E-023-2006/0-AU-03)
  • Canadian Patent Application No. 2,627,686 filed 02 Nov 2006 (HHS Reference No. E-023-2006/0-CA-04)
  • European Patent Application No. 06836855.4 filed 02 Nov 2006 (HHS Reference No. E-023-2006/0-CA-04)
  • Japanese Patent Application No. 2008-539046 filed 01 May 2008 (HHS Reference No. E-023-2006/0-JP-06)

 

Inventors: 

Cigdem F. Dogulu, Owen M. Rennert, Wai-Yee Chan (NICHD)

Type of business relationship sought

Licensing Status: 

Available for exclusive or non-exclusive licensing.

 

Collaborative Research Opportunity: 

The NICHD Section on Clinical Genomics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method Evolved for Recognition and Testing of Age-Related Macular Degeneration (MERT-ARMD).  Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.

Licensing contact

Jennifer Wong
Licensing and Patenting Manager
Office of Technology Transfer

Contact directly

Company details

National Institutes of Health (NIH)

The NIH supports and conducts basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Innovaro Pharmalicensing current industry press releases.

© Copyright 1998-2010 Innovaro Pharmalicensing, a division of Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us